Given that T2DM is characterized by insulin resistance, hyperinsulinemia and impaired insulin signalling, it is not surprising that an increased GSK-3β activity in T2DM might lead to an elevation of Aβ production [56] and increased tau phosphorylation [57]. Here, MAPT is linked to Hyperinsulinemia.